PIDOLIC ACID

Possibly Marketed Outside US

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C5H7NO3
Molecular Weight	129.114
Optical Activity	( - )
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)[C@@H]1CCC(=O)N1

InChI

InChIKey=ODHCTXKNWHHXJC-VKHMYHEASA-N

InChI=1S/C5H7NO3/c7-4-2-1-3(6-4)5(8)9/h3H,1-2H2,(H,6,7)(H,8,9)/t3-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C5H7NO3
Molecular Weight	129.114
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.currentscience.ac.in/Volumes/102/02/0288.pdfhttps://www.drugs.com/otc/121041/cleansing-foaming-gel-acne-pro-skin.html | https://www.ncbi.nlm.nih.gov/pubmed/25727335 | https://www.ncbi.nlm.nih.gov/pubmed/21834944 | https://www.ulprospector.com/en/na/PersonalCare/Detail/6637/223524/EcoCare-Zinclean | http://www.scalp-health.com/zinc-pca.htm
Curator's Comment: description was created based on several sources, including http://www.cir-safety.org/sites/default/files/pca.pdf

Zinc Pidolate (Zinc PCA) is a topical skin product with purifying, astingent, anti-inflammatory, antiseptic activity. It has long been used as a cosmetic ingredient, because of its astringent and anti-microbial properties. Zinc Pidolate has also being shown to be effective against halitosis. Zinc PCA prevents the UV-induced MMP-1 production in vitro by suppressing the activation of AP-1. Zinc PCA was also able to enhance type I collagen synthesis in NHDFs, by increasing the expression of the mRNA encoding the ascorbic acid transporter SVCT2 in non-UV irradiated NHDFs, which suggests its promising effect against not only photoaged skin but also for the simple atrophic change of intrinsic skin ageing. Zinc PCA is able to suppress sebum secretion by inhibiting 5-α reductase in hyperseborrhea, to suppress body odor by forming zinc salts with short-chain fatty acids, to suppress wrinkles by inhibiting AP-1 to and inhibit bacterial growth including acne related Propionibacterium acnes.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Sodium-dependent vitamin C transporter 2 5 Target ID: CHEMBL3271 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21834944	Activator 1447
Collagen alpha-1(I) chain 11 Target ID: P02452\|\|\|Q15176\|\|\|Q9UML6 Gene ID: 1277.0 Gene Symbol: COL1A1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/21834944	Activator 1447
Transcription factor AP1 6 Target ID: CHEMBL2111421 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21834944	Activator 1447
Propionibacterium acnes 6 Target ID: CHEMBL612639 Sources: http://www.in-cosmetics.com/__novadocuments/4317 \| https://www.ulprospector.com/en/na/PersonalCare/Detail/6637/223524/EcoCare-Zinclean	Inhibitor 8504
Steroid 5-alpha-reductase 15 Target ID: CHEMBL2363075 Sources: https://www.ulprospector.com/en/na/PersonalCare/Detail/6637/223524/EcoCare-Zinclean \| www.google.com/patents/US20090203628 \| http://www.in-cosmetics.com/__novadocuments/4317	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Acne 100 Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=cab1d71c-e017-4ff3-853b-b0e47dc1ee79&type=display http://www.solabia.com/Produto_7,1/Cosmetics/Zincidone.html http://www.scalp-health.com/zinc-pca.htm	Preventing	Approved 8583	CLEANSING FOAMING GEL ACNE PRO SKIN- zinc pidolate gel Approved Use Lange Gel will turn into foam, during application. It will cleanse skin thoroughly without any dryness effect, in order to avoid hyperseboohea phenomenon, a main cause of acne. Launch Date 2012
Halitosis 6 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25727335	Primary	Phase I 438	Unknown Approved Use Unknown
Seborrhea 11 Sources: http://www.in-cosmetics.com/__novadocuments/4317 http://www.scalp-health.com/zinc-pca.htm http://www.solabia.com/Produto_7,1/Cosmetics/Zincidone.html http://cosmetics.specialchem.com/product/i-ecochem-ecocare-zinclean	Primary	Approved 8583	EcoCare™ Zinclean Approved Use Use in anti-dandruff shampoos
Dry skin 6 Sources: http://www.cir-safety.org/sites/default/files/pca.pdf	Primary	Approved 8583	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
The X-ray crystal structure of pyrrolidone-carboxylate peptidase from hyperthermophilic archaea Pyrococcus horikoshii.	2002	12836705
Expression and prognostic significance of lysozyme in male breast cancer.	2002	12473177
Continuous spectrometric assays for glutaminyl cyclase activity.	2002 Apr 1	11906150
Spectrophotometric assays for L-lysine alpha-oxidase and gamma-glutamylamine cyclotransferase.	2002 Apr 15	11950211
CLAC: a novel Alzheimer amyloid plaque component derived from a transmembrane precursor, CLAC-P/collagen type XXV.	2002 Apr 2	11927537
Complete structure of an increasing capillary permeability protein (ICPP) purified from Vipera lebetina venom. ICPP is angiogenic via vascular endothelial growth factor receptor signalling.	2002 Aug 16	12021274
Generation of amyloid beta peptide with pyroglutamate at position 3 in primary cortical neurons.	2002 Jul 12	12098492
Allatostatins of the tiger prawn, Penaeus monodon (Crustacea: Penaeidea).	2002 Jun	12126730
Stereoselective total syntheses of the racemic form and the natural enantiomer of the marine alkaloid lepadiformine via a novel N-acyliminium ion/allylsilane spirocyclization strategy.	2002 Jun 14	12054972
Two novel antifungal peptides distinct with a five-disulfide motif from the bark of Eucommia ulmoides Oliv.	2002 Jun 19	12067732
Pseudopeptide foldamers: the homo-oligomers of pyroglutamic acid.	2002 Jun 3	12180330
[Effect of a drug composition containing pyroglutamic acid and pyrrolidone on the cerebral circulation].	2002 May-Jun	12227092
Fluorometric assay using naphthylamide substrates for assessing novel venom peptidase activities.	2002 Nov	12419513
Synthesis and preliminary evaluation of trans-3,4-conformationally-restricted glutamate and pyroglutamate analogues as novel EAAT2 inhibitors.	2002 Nov 4	12372536
Methacrylate derivatives incorporating pyroglutamic acid.	2002 Nov-Dec	12425681
Production of pyroglutamic acid by thermophilic lactic acid bacteria in hard-cooked mini-cheeses.	2002 Oct	12416800
Heterologous expression and characterization of human glutaminyl cyclase: evidence for a disulfide bond with importance for catalytic activity.	2002 Sep 3	12196024
Stereoselective synthesis of dipeptide beta-turn mimetics: 7-benzyl and 8-phenyl substituted azabicyclo[4.3.0]nonane amino acid esters.	2002 Sep 6	12201753
Characterization and sequence of tomato 2S seed albumin: a storage protein with sequence similarities to the fruit lectin.	2003 Apr	12687365
Pigment-epithelium-derived factor (PEDF) occurs at a physiologically relevant concentration in human blood: purification and characterization.	2003 Aug 15	12737624
Refolding of amphioxus insulin-like peptide: implications of a bifurcating evolution of the different folding behavior of insulin and insulin-like growth factor 1.	2003 Aug 19	12911310
Beta-lactams as versatile synthons for homochiral ibotenate analogues with potential for activity at glutamate receptors.	2003 Aug 7	12948191
Solution structure of the cytotoxic RNase 4 from oocytes of bullfrog Rana catesbeiana.	2003 Feb 28	12589762
Isolation and identification of indigestible pyroglutamyl peptides in an enzymatic hydrolysate of wheat gluten prepared on an industrial scale.	2003 Jan 1	12502378
[Neuroprotective properties of pyroglutamic acid in combination with pyrrolidone].	2003 Jan-Feb	12683075
Characterization of a new bradykinin-potentiating peptide (TmF) from Trimeresurus mucrosquamatus.	2003 Jul	12883631
Pyrrolidinones derived from (S)-pyroglutamic acid: penmacric acid and analogues.	2003 Jul 7	12945710
2,5-Disubstituted pyrrolidines: versatile regioselective and diastereoselective synthesis by enamine reduction and subsequent alkylation.	2003 Jun 7	12945761
Reinvestigation of the proposed folding and self-association of the Neuropeptide Head Activator.	2003 Mar	12592026
[Evolution of the neuroprotection concept].	2003 Mar-Apr	12962045
[Oleyl pyroglutamate for use as transdermal enhancer and its enhancing mechanism].	2003 May	12958846
Proinsulin C-peptide and its C-terminal pentapeptide: degradation in human serum and Schiff base formation with subsequent CO2 incorporation.	2003 May	12827290
[Characteristics of pyrrolidone pharmacokinetics in rats].	2003 Nov-Dec	14743713
Structural characterization of native mouse zona pellucida proteins using mass spectrometry.	2003 Sep 5	12799386
Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions.	2004 Apr 9	15063747
Glutamine in commercial liquid nutritional products.	2004 Aug 11	15291459
Toward the synthesis of pyroglutamate lauroyl ester: biocatalysis versus chemical catalysis.	2004 Feb	15049361
Stabilization of peptide guinea pig myelin basic protein 72-85 by N-terminal acetylation-implications for immunological studies.	2004 Feb	14725790
Human glutaminyl cyclase and bacterial zinc aminopeptidase share a common fold and active site.	2004 Feb 10	15028118
Unexplained metabolic acidosis in critically ill patients: the role of pyroglutamic acid.	2004 Mar	14685659
Synthesis of (2S,3R)-[3',3',3'-2H3]-valine and (2S,3S)-4-fluorovaline.	2004 May 7	15105921
The development of a higher throughput reactive intermediate screening assay incorporating micro-bore liquid chromatography-micro-electrospray ionization-tandem mass spectrometry and glutathione ethyl ester as an in vitro conjugating agent.	2004 Sep 21	15351054
The computer modelling of human TRH receptor, TRH and TRH-like peptides.	2005	15544424
Formation of extracellular glutamate from glutamine: exclusion of pyroglutamate as an intermediate.	2005 Aug 2	16004974
Stereoselective synthesis of conformationally constrained omega-amino acid analogues from pyroglutamic acid.	2005 Aug 7	16032366
Physiological and pathological aspects of GSH metabolism.	2005 Feb	15981742
CLPM: a cross-linked peptide mapping algorithm for mass spectrometric analysis.	2005 Jul 15	16026606
Total synthesis of pinnamine and anatoxin-a via a common intermediate. A caveat on the anatoxin-a endgame.	2005 Jul 8	15989354
Bromophenols coupled with derivatives of amino acids and nucleosides from the red alga Rhodomela confervoides.	2005 May	15921411
Synthesis of 1,3-dioxo-hexahydropyrido[1,2-c][1,3]diazepine carboxylates, a new bicyclic skeleton formed by ring expansion-RCM methodology.	2005 Sep 21	16136256

Patents

Sample Use Guides

In Vivo Use Guide

Topical, as a compontent of lotions, creams and other cosmetic products.

Route of Administration: Topical

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Wed Apr 02 07:52:53 GMT 2025` Edited by `admin` on `Wed Apr 02 07:52:53 GMT 2025`
Record UNII	SZB83O1W42
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PCA	Locators: INCI Naming Organization: INCI Sources:

Preferred Name

English

PIDOLIC ACID

Official Name

English

GLP

Common Name

English

L-PYROGLUTAMIC ACID

Common Name

English

PYROGLUTAMIC ACID

Common Name

English

5-OXO-L-PROLINE

Systematic Name

English

AJIDEW A-100

Brand Name

English

Pidolic acid [WHO-DD]

Common Name

English

PYROGLUTAMIC ACID, L-

Common Name

English

L-PYRROLIDONE CARBOXYLIC ACID

Common Name

English

5-L-OXOPROLINE

Common Name

English

5-OXOPROLINE

Common Name

English

L-PCA

Common Name

English

PYROGLUTAMATE

Common Name

English

PYROGLU

Common Name

English

pidolic acid [INN]

Common Name

English

PIDOLIDONE

Brand Name

English

L-PYROGLUTAMIC ACID [MI]

Common Name

English

5-OXO-2-PYRROLIDINECARBOXYLIC ACID

Systematic Name

English

(-)-2-PYRROLIDONE-5-CARBOXYLIC ACID

Systematic Name

English

PYROGLUTAMIC ACID [USP-RS]

Common Name

English

GLUTIMIC ACID

Common Name

English

NSC-143034

Code

English

NSC-760414

Code

English

Classification Tree Code System Code

LOINC

75089-3